Philip J. Vickers - 01 Apr 2026 Form 4 Insider Report for Akebia Therapeutics, Inc. (AKBA)

Reporting relationship: Director
Issuer ticker: AKBA
Reported as of: 01 Apr 2026
Net transaction value: $0
SEC form: 4
Accepted by SEC: 03 Apr 2026, 16:06:54 UTC
Prior SEC filing: 08 Jun 2023
Source filing: View source filing
Reporting owner signature: /s/ Carolyn M. Rucci, attorney-in-fact for Philip J. Vickers

Key filing fact

Philip J. Vickers filed Form 4 for Akebia Therapeutics, Inc. (AKBA) on 03 Apr 2026.

Key facts

This page summarizes Philip J. Vickers's Form 4 filing for Akebia Therapeutics, Inc. (AKBA).
1 reported transaction and 1 derivative row are listed below.
Accepted by SEC: 03 Apr 2026, 16:06.

Change

Previous filing in this sequence was filed on 08 Jun 2023.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001635046 Primary reporting owner

Vickers Philip J.

Relationship: Director
Address: C/O AKEBIA THERAPEUTICS, INC, 245 FIRST STREET, CAMBRIDGE
Signature: /s/ Carolyn M. Rucci, attorney-in-fact for Philip J. Vickers
Signature date: 03 Apr 2026

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

AKBA transaction Derivative

Stock Option (Right to buy)

Award

Transaction value
Shares: +214,400
Change %
Price: $0.000000^*
Shares after: 214,400
Date: 01 Apr 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 214,400
Exercise price: $1.41
Footnotes: F1

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 1 footnote

Footnote F1

The option to purchase shares of the Issuer's common stock (the "Stock Option") was granted by the Issuer pursuant to the 2023 Plan, as provided by the Fifth Amended and Restated Non-Employee Director Compensation Program. The Stock Option will vest over three years: 33 1/3 % of the options will vest on the first anniversary of the grant date and the remaining 66 2/3 % will vest ratably on the first day of each calendar quarter thereafter, subject to the Reporting Person's continued service to the Issuer.